Skip to main content

25-10-2023 | NSCLC | Expert Interview | Article | Illumina, Inc., and Eli Lilly and Company

Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs


Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint. 

00:00 – Introduction from Professor Beggs
02:00 – Biopsy types for NGS
06:50 – DNA versus RNA for analysis
12:37 – Processing considerations – an NHS case study
15:30 – Integrating genomic profiling into patient care and management
22:12 – Conclusions


  • Prof. Andrew Beggs
    Institute of Cancer and Genomic Sciences, University of Birmingham, UK. Read more

Speaker disclosures

  • Grant funding: AstraZeneca Plc, Incyte Inc, MSD, Moderna, Oxford Nanopore, Thermo Scientific, Illumina, BioNano, Innova Medical
  • Travel & conference funding: Oxford Nanopore, Thermo Scientific, Illumina, Bayer
  • Consultancy: Oxford Nanopore, Check4Cancer, Kiffik Biomedical, 2CureX Ag
  • In kind support: MGITech, Illumina, Congenica, Qiagen 
  • Salary support: MRC Senior Clinical Fellowship

Financial disclosure 

This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.


Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Related topics

Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare